Article
Medicine, Research & Experimental
Ayumu Matsuoka, Shinichi Tate, Kyoko Nishikimi, Masami Iwamoto, Satoyo Otsuka, Makio Shozu
Summary: In this retrospective cohort study, further classification of FIGO stage IIIA1 cancer was not significantly associated with patient outcomes.
Article
Oncology
Hyeong In Ha, Eun Young Park, Kyung Jin Eoh, Yeon Jee Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
Summary: This study investigated the clinical significance of the ovarian cancer cluster region (OCCR) in BRCA1 and BRCA2 genes. The results showed that patients with BRCA1 pathogenic variants (PVs) in the OCCR region had shorter progression-free survival (PFS) compared to those outside the OCCR. This trend was more pronounced in the platinum-sensitive subgroup. However, no significant differences were found in overall survival (OS) between patients with BRCA1/2 PVs, regardless of the variant location.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Ji young Kim, Haeil Park, Dae woo Lee, Min jeong Kim, Jae eun Shin, Kyung eun Lee, Hae nam Lee
Summary: This study analyzed the survival outcomes and clinical factors associated with the prognosis of patients with epithelial ovarian, peritoneal, or fallopian tube cancer with BRCA1/2 mutations. The results showed that having a germline BRCA1/2 mutation improved short-term progression-free survival (PFS) in these patients. Primary neoadjuvant chemotherapy and elevated initial CA125 level were related to poor prognosis.
ANTICANCER RESEARCH
(2022)
Article
Nutrition & Dietetics
Naoko Nomoto, Shinichi Tate, Makoto Arai, Shinji Iizaka, Chisato Mori, Kenichi Sakurai
Summary: This study investigates the relationship between nutritional status before chemotherapy and chemotherapy discontinuation. The study finds that C-reactive protein-to-albumin ratio (CAR) can effectively predict the risk of chemotherapy interruption.
Article
Oncology
John B. Liao, William R. Gwin, Renata R. Urban, Katie M. Hitchcock-Bernhardt, Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, Hania N. Shakalia, Ron E. Swensen, Sasha E. Stanton, Anna Tinker, Tanya A. Wahl, Richard G. Ancheta, Kathryn F. McGonigle, James Y. Dai, Mary L. Disis, Barbara A. Goff
Summary: The study evaluated the activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer, showing that this treatment approach had modest activity and good tolerability. A ratio of peripheral T-cell exhaustion to radiographic tumor burden may help identify patients who are more likely to benefit from this chemoimmunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Tova M. Bergsten, Sarah E. Levy, Katherine E. Zink, Hannah J. Lusk, Melissa R. Pergande, Stephanie M. Cologna, Joanna E. Burdette, Laura M. Sanchez
Summary: This study discovered that a secreted protein called SPARC, produced by tumorigenic fallopian tube epithelial cells, enhances the release of norepinephrine (NE) from the ovary, influencing the primary metastasis of high grade serous ovarian cancer (HGSOC).
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Hyeong In Ha, Eun-Gyeong Lee, Jiwon Lim, So-Youn Jung, Yoon Jung Chang, Young-Joo Won, Myong Cheol Lim
Summary: The incidence of secondary primary POFT cancer after breast cancer increased in Korea between 1999 and 2017. Second primary POFT cancer patients were diagnosed at older ages and had more serous histology.
CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Jocelyn C. Reader, Pei Hui, Joan R. Tymon-Rosario, Justin Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Alessandro D. Santin
Summary: This multi-center study evaluated the activity and safety of ixabepilone plus bevacizumab compared to ixabepilone alone in platinum-resistant/refractory ovarian cancer. The results showed that the combination of ixabepilone and bevacizumab had a higher overall response rate and longer progression-free survival, with good tolerability. Prior receipt of bevacizumab should not limit the use of ixabepilone plus bevacizumab in treatment.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Hideki Tokunaga, Mikio Mikami, Satoru Nagase, Yoichi Kobayashi, Tsutomu Tabata, Masanori Kaneuchi, Toyomi Satoh, Yasuyuki Hirashima, Noriomi Matsumura, Yoshihito Yokoyama, Kei Kawana, Satoru Kyo, Daisuke Aoki, Hidetaka Katabuchi
Summary: The Japan Society of Gynecologic Oncology published the fifth edition of guidelines for ovarian cancer, fallopian tube cancer, and primary peritoneal cancer treatment in 2020. The guidelines include 6 chapters and 5 algorithms, with major changes such as revised title, broader involvement, new clinical question format, and modified recommendations based on the GRADE system.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Pia Leandersson, Thomas Hogberg, Paul W. Dickman, Susanne Malander, Christer Borgfeldt
Summary: Overall incidence of ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers in Sweden has declined since 1980. The median age at diagnosis has increased, with an increase in incidence of serous carcinoma. Survival rates at 1, 2, and 5 years have improved since 1960, but 10-year survival remains poor. Fallopian tube cancer has the best survival rates, while undesignated abdominal/pelvic cancer has the worst.
Article
Oncology
Floor J. Backes, Lai Wei, Min Chen, Kasey Hill, Kyle Dzwigalski, Ming Poi, Mitch Phelps, Ritu Salani, Larry J. Copeland, Jeffrey M. Fowler, David E. Cohn, Kristin Bixel, Casey Cosgrove, John Hays, David O'Malley
Summary: This study aimed to estimate the maximally tolerated dose and toxicities of lenvatinib and paclitaxel in patients with recurrent endometrial and platinum resistant epithelial ovarian cancer, and observed encouraging activity in both types of cancer, indicating the need for further development.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Cell Biology
Maxence Wisztorski, Soulaimane Aboulouard, Lucas Roussel, Marie Duhamel, Philippe Saudemont, Tristan Cardon, Fabrice Narducci, Yves-Marie Robin, Anne-Sophie Lemaire, Delphine Bertin, Nawale Hajjaji, Firas Kobeissy, Eric Leblanc, Isabelle Fournier, Michel Salzet
Summary: This study conducted an in-depth proteomic analysis of pre-neoplastic epithelial lesions in ovarian cancer using mass spectrometry imaging and immunohistochemistry techniques. Specific lesion markers were identified, and a lipidomic analysis confirmed the presence of specific lipid signatures in these lesions. The study provides new insights into the molecular mechanisms underlying the progression of ovarian cancer and confirms the fimbria origin of high-grade serous carcinoma.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Robert Armbrust, Peter Ledwon, Anne Von Rusten, Constanze Schneider, Jalid Sehouli
Summary: Diagnosis and treatment of ovarian cancers have evolved over the years. This study presents a major analysis of federal cancer registry data in Germany, showing good treatment outcomes in patients with primary ovarian cancer. However, there are areas for improvement, and new quality indicators can be established to enhance treatment outcomes.
Review
Oncology
Ju Yoon Yoon, David B. Chapel, Emily Goebel, Xiaohua Qian, Jeffrey K. Mito, Neil S. Horowitz, Alexander Miron, T. Rinda Soong, Wa Xian, Christopher P. Crum
Summary: The current theory of carcinogenesis for high-grade serous carcinoma (HGSC), the deadliest form of ovarian cancer, suggests that the malignancy originates in the fallopian tube and then spreads to the ovaries, peritoneum, and/or regional lymph nodes. However, the occurrence of early forms of the disease in the general population is rare, and the risk of developing HGSC after their removal is low. It is still unclear whether tubal or ovarian HGSCs encountered in advanced disease evolve in the same way.
JOURNAL OF PATHOLOGY
(2022)
Article
Oncology
Jonathan S. Berek, Xavier Matias-Guiu, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, David Mutch, Endometrial Canc Staging Subcomm, FIGO Womens Canc Comm
Summary: Since the 2009 update of the FIGO staging system, there have been significant advances in understanding the pathologic and molecular features of endometrial cancer. The new staging system aims to better define prognostic groups and create substages to guide more appropriate treatment.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)